Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
株式のランク #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
株価
$32.88
時価総額
$2.08B
変化(1日)
-0.48%
変化(1年)
96.77%
US
取引 Zenas BioPharma, Inc. (ZBIO)

カテゴリー

Zenas BioPharma, Inc.(ZBIO)の株価履歴
終値の最高値: $31.75 (2026-08-01)

終値の最安値: $17.96 (2024-09-01)
Zenas BioPharma, Inc. の株価履歴(2024 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -33.58%
2025 294.97%
2024 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH